Introduction {#S1}
============

The use of animals for scientific purposes goes back to ancient Greece where philosophers and scientists such as Alcmaeon of Croton, Aristotle, and Erasistratus dissected animals for anatomical studies. Today, the use of animals is a general practice for studying human biology and disease as the genetic similarity between humans and mice is very high. Also, the rapid development of methods for creating genetically modified animals increases their scientific value and stimulates general interest in preclinical research in society. One of the mouse models for laminin α2 chain-deficiency, the spontaneous *dy/dy* mutant, was described in 1955. It was the first reported mouse strain representing the pathological criteria that were characteristic for muscular dystrophy. The hereditary pattern of the defects suggested an autosomal recessive disorder and the causative mutation was called *dystrophia muscularis*, designated by the symbol *dy* ([@B77]). Understandably, at that time it was not linked to any specific inherited muscle disease but in 1994 two independent research groups suggested that deficiency of laminin α2 chain might be the primary defect in *dy/dy* mice ([@B107]; [@B123]). Yet, until this date the mutation in the *Lama2* gene in the *dy/dy* mouse has not been identified.

Overview of LAMA2-CMD Mouse Models {#S2}
==================================

More than 300 mutations in the *LAMA2* gene have been identified so far in patients ([@B92]), which result in a large clinical heterogeneity of the disease. Realistically, the whole range of human mutations cannot be mimicked in mice, but currently available mouse models mirror well the broad spectrum of the human LAMA2-CMD condition ([Table 1](#T1){ref-type="table"}). This creates an opportunity for more efficient preclinical testing and conclusive preclinical studies.

###### 

Summary of available LAMA2-CMD mouse models.

  **Mouse**                       **Mutation**                                                    **Laminin α2 expression**                                               **Phenotype^\#^**                                       **Time of death**        **References**
  ------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------- ------------------------ -------------------------------------
  *dy/dy*                         Spontaneous, unknown                                            Reduced expression of normal sized laminin α2                           Moderate muscular dystrophy Peripheral neuropathy       Before 6 months of age   [@B107]; [@B123]
  *dy*^2J^/*dy*^2^                Spontaneous splice site mutation in LN domain                   Slightly reduced expression of truncated laminin α2 missing LN domain   Mild muscular dystrophy Peripheral neuropathy           After 6 months of age    [@B124]; [@B108]
  *dy*^6J^/*dy*^6J^               Spontaneous, unknown                                            Unknown                                                                 Moderate (?) muscular dystrophy Peripheral neuropathy   Before 6 months of age   <https://www.jax.org/strain/003589>
  *dy*^7J^/*dy*^7J^               ENU-induced missense mutation in LN domain                      Normal levels of normal sized laminin α2                                Mild muscular dystrophy Peripheral neuropathy           After 6 months of age    [@B94]
  *dy*^W^/*dy*^W^                 Knock-out                                                       Severely reduced expression of truncated laminin α2 missing LN domain   Severe muscular dystrophy Peripheral neuropathy         5--12 weeks of age       [@B64]; [@B121]
  *dy*^3K^/*dy*^3K^               Knock-out                                                       Complete deficiency                                                     Very severe muscular dystrophy Peripheral neuropathy    3 weeks of age           [@B80]
  *dy*^8J^/*dy*^8J^ (extinct)     Spontaneous, unknown                                            Unknown                                                                 Severe (?) muscular dystrophy Peripheral neuropathy     3--4 weeks of age        <https://www.jax.org/strain/009692>
  *dy*^Pas^/*dy*^Pas^ (extinct)   Spontaneous, retrotransposal insertion between exon 34 and 35   Complete deficiency                                                     Severe muscular dystrophy Peripheral neuropathy         Before 13 weeks of age   [@B5]

The symbol "\#" denotes description of muscular dystrophy severity (mild, moderate, severe, and very severe). The severity is based on age of onset, histopathological severity and time of death. The symbol "?" denotes characterization of mice remains to be published. Description of severity is based on information on

https://www.jax.org/

.

The three most commonly used animal models for LAMA2-CMD are *dy*^2J^/*dy*^2J^ ([@B124]; [@B108]), *dy*^3K^/*dy*^3K^ ([@B80]), and *dy*^W^/*dy*^W^ mice ([@B64]; [Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Skeletal muscle and peripheral nerve are the tissues with the most evident pathology in LAMA2-CMD mutants ([@B134]). The dystrophic symptoms and general muscle pathology at the advanced stages of the disease have been fairly well characterized in all three models ([@B124]; [@B80]; [@B64]; [@B81]; [@B43]; [@B40], [@B39]; [@B36], [@B37]; [@B8]; [@B66]; [@B93]). Yet, we still need to learn more about mechanisms driving the disease progression in mouse. Only recently the importance of the embryonic, pre-symptomatic stages and early pathogenesis in the different mouse models for LAMA2-CMD has been emphasized ([@B30], [@B31]; [@B72]; [@B90]; [@B83]). Likewise, associated symptoms in non-muscle tissues (peripheral and central nervous system, cardiorespiratory system) have gained attention ([@B47]; [@B98], [@B97]; [@B128]; [@B32], [@B37], [@B55]; [@B76]; [@B121]; [@B93]; [@B100]).

![General phenotype of dystrophic LAMA2-CMD mice (*dy*^2J^/*dy*^2J^, *dy*^W^/*dy*^W^ and *dy*^3K^/*dy*^3K^) and their normal littermates (WT) at 3 weeks of age. Muscle wasting and weight loss are evident in *dy*^W^/*dy*^W^ and *dy*^3K^/*dy*^3K^ mice.](fnmol-13-00059-g001){#F1}

Below we present a concise overview of the pathology in the three mouse models.

Phenotype of *dy*^2J^/*dy*^2J^ Mice {#S2.SS1}
-----------------------------------

*dy*^2J^/*dy*^2J^ mice carry a splice site mutation in the LN domain, which results in production of a shorter laminin α2 chain lacking the N-terminal portion of the molecule ([@B124]; [@B108]). The truncation hinders polymerization of laminin matrices and formation of basement membranes ([@B13]; [@B132]; [@B133]), but the phenotype of *dy*^2J^/*dy*^2J^ mice is relatively mild ([@B43]) (phenotype overview: [Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Their survival extends over 6 months of age ([@B124]). Although the majority of dystrophic features are similar between *dy*^2J^/*dy*^2J^ males and females (dystrophic features in different muscle types) ([@B93]), one has to take into consideration that gender-related phenotype differences (weight gain, creatine kinase levels (CK), water intake, muscle strength), exist in this mouse model ([@B24]; [@B83]; [@B93]), which thus far has not been demonstrated for other LAMA2-CMD mutants. While these differences do not impact the overall disease presentation (they are rather subtle and a more severe phenotype cannot be attributed to any gender), they could significantly influence the outcomes of therapeutic strategies ([@B24]). Hence, analysis of the treatment effects in *dy*^2J^/*dy*^2J^ mice should take into account both genders separately.

###### 

An overview of time-points describing the disease progress in LAMA-CMD mouse models (*dy*^2J^/*dy*^2J^, *dy*^W^/*dy*^W^, *dy*^3K^/*dy*^3K^) based on muscle pathology.

                      **Disease progress (age)**                                                                  
  ------------------- ----------------------------------------------- ------------------------------- ----------- ----------------------------------------------------------------
  *dy*^2J^/*dy*^2J^   Time-point not determined                       Time-point not determined       Week 3--4   Week 6 onward
  *dy*^W^/*dy*^W^     E10.5--E17                                      E17.5--E18.5, smaller muscles   Week 1--2   Week 3--15
  *dy*^3K^/*dy*^3K^   E18.5 (earlier time-points were not analyzed)   Postnatal day 1, apoptosis      Week 1      Week 2--3, despite improvements of muscle morphology (plateau)

Onset: the first signs of muscle pathology. Early disease: muscle damage, inflammation and regeneration. Established disease: fibrosis, atrophy in addition to hallmarks mentioned earlier. Please note that only a few muscles were included in most of the studies and often a limited number of phenotyping methods was applied.

###### 

A summary of the overall health and muscle phenotype of LAMA2-CMD mouse models (*dy*^2J^/*dy*^2J^, *dy*^W^/*dy*^W^, *dy*^3K^/*dy*^3K^) at the different stages of development.

                      **Developmental stage**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  *dy*^2J^/*dy*^2J^   Not determined.                                                                                Not determined.                                                                                                                          Week 1--2 not determined. Pronounced inflammation and increased CK at week 3.                                                                                                                                       Central nucleation, inflammation, muscle fiber size variation, weight loss, CK variable, impaired muscle function. Phenotype clearly visible outwardly.                                                                               Fibrosis, central nucleation, fiber size variation. Impaired neuromuscular function.
  *dy*^W^/*dy*^W^     Normal back muscle morphology, smaller muscle size from E18.5, more detailed studies needed.   Smaller back muscles, limb muscles normal size. Morphology abnormalities, apoptosis, inflammation.                                       Atrophy (smaller limb muscles, muscle fiber loss), apoptosis, central nucleation, inflammation, fibrosis onset. Phenotype clearly visible outwardly.                                                                Apoptosis, inflammation, central nucleation, muscle fiber loss, fibrosis, increased CK, muscle function impairment.                                                                                                                   Apoptosis, inflammation muscle fiber loss, atrophy, fibrosis, increased CK, muscle function impairment.
  *dy*^3K^/*dy*^3K^   Normal limb muscle, more detailed studies needed.                                              Apoptosis, muscle degeneration, muscle fiber loss, inflammation, central nucleation, weight loss. Phenotype clearly visible outwardly.   Muscle repair, atrophy (smaller muscle fibers), apoptosis, inflammation, increased extracellular matrix deposition. Impaired motor function. Abnormalities of masticatory muscles. Increased CK, death at week 3.   Currently NA (death at age of 3 weeks). In previous studies when *dy*^3K^/*dy*^3K^ mice survived up to 5 weeks: Apoptosis, inflammation, central nucleation, muscle fiber loss, fibrosis, increased CK, muscle function impairment.   NA (death at age of 3 weeks).

NA -- not applicable.

![Different stages of muscle pathology in three LAMA2-CMD mouse models (*dy*^2J^/*dy*^2J^, *dy*^W^/*dy*^W^, and *dy*^3K^/*dy*^3K^). Limb muscles (rectus femoris for *dy*^2J^/*dy*^2J^ and *dy*^3K^/*dy*^3K^, triceps for *dy*^W^/*dy*^W^) were stained with hematoxylin and eosin. Yellow arrows point to regenerating fibers with centrally located nuclei; turquoise arrows depict areas with inflammatory cells. Bars, 100 μm.](fnmol-13-00059-g002){#F2}

The pre-symptomatic stages of the disease in the *dy*^2J^/*dy*^2J^ mouse have not been delineated. The earliest time-point analyzed is 3 weeks of age and at this stage *dy*^2J^/*dy*^2J^ animals show normal muscle strength and collagen content in muscle is not changed ([@B83]). However, muscle damage has already taken place as demonstrated by elevated CK levels, pronounced inflammatory response and occurrence of regenerating fibers ([Figure 2](#F2){ref-type="fig"}; [@B58]; [@B83]). Additionally, 3-week-old *dy*^2J^/*dy*^2J^ males weigh less than wild-type male littermates. One week later, other dystrophic hallmarks (central nucleation, decreased muscle strength) are established and fully developed pathology can be observed at 6--8 weeks of age, including increased production of several extracellular matrix components, muscle atrophy and decreased body weights in both genders ([@B86]; [@B70]; [@B24]; [@B83]; [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Reduced muscle strength and mobility between 4--10 weeks of age has been clearly documented in several studies ([@B16]; [@B70]; [@B24]; [@B37]; [@B83]; [@B93]). The follow-up of the *dy*^2J^/*dy*^2J^ mouse condition up to 34 weeks of age did not reveal significant muscle pathology progression compared to 6-week-old mice ([@B93]), except for the additional body weight loss between week 6--10 ([@B24]). In contrary, the CK levels were normalized with age ([@B54]; [@B93]) and challenging the mice with functional tests throughout the course of the disease (between week 6 and 34) did not worsen the dystrophic symptoms ([@B93]). It is also important to mention that different muscles display variation in the severity of the phenotype (gastrocnemius and tibialis anterior are more affected than triceps; diaphragm shows mild pathology) and distinct patterns of pathology development (for example different timing and degree of inflammation) ([@B37]; [@B58]; [@B93]).

Due to its prolonged survival time compared to other mouse models, the *dy*^2J^/*dy*^2J^ mouse is widely used for studies of peripheral neuropathy associated with laminin α2 chain-deficiency ([@B128]; [@B37]; [@B100]). The first signs of peripheral neuropathy (hind limb clasping when lifted by tail) are visible 4 weeks after birth and aggravate with age. Temporary hind limb paralysis (symptoms ceasing and relapsing, often in one limb only) occurs already around week 6 and permanent hind limb paralysis by 3 months of age ([@B128]) (it is noteworthy that forelimbs, at least outwardly, are not affected). These symptoms are caused by impaired axonal sorting and dysmyelination ([@B128]; [@B37]), particularly in motor nerves (ventral roots), but also in dorsal roots ([@B128]; [@B100]). Accordingly, motor nerve conduction velocity in the sciatic nerve is reduced ([@B19]; [@B100]). It is important to mention that peripheral nerve defects cause neurogenic atrophy of muscle fibers ([@B34]; [@B71]) and contribute to dystrophic phenotype of skeletal muscle. Interestingly, although peripheral neuropathy is pronounced in all LAMA2-CMD mouse models ([@B43]), it is rarely manifested in patients ([@B134]).

Respiratory function in *dy*^2J^/*dy*^2J^ mice has been assessed with the whole-body plethysmography. The respiratory rate and amplitude were significantly impaired in *dy*^2J^/*dy*^2J^ mice and the respiration rate further declined with age ([@B130]; [@B93]). Cardiac manifestations are associated with some cases of LAMA2-CMD (mostly attributed to complete absence of laminin α2 chain) ([@B87]). Cardiomyopathy has not been observed in *dy*^2J^/*dy*^2J^ mice as assessed by histological means (8-week-old animals) ([@B37]) and echocardiography (12--15 and 30--33 week-old animals) ([@B130]). Yet, the heart rates are increased in *dy*^2J^/*dy*^2J^ mutants ([@B130]) and hearts from 10-week-old dystrophic mice tend to weigh less ([@B24]) than wild-type hearts. In the light of growing evidence that cardiac defects in patients (also with partial deficiency of laminin) could be underreported in literature ([@B87]), it is possible that histological features of cardiomyopathy may be manifested in hearts from older *dy*^2J^/*dy*^2J^ animals, despite no clear changes in electrophysiological parameters.

Phenotype of *dy*^W^/*dy*^W^ Mice {#S2.SS2}
---------------------------------

The *dy*^W^/*dy*^W^ mouse was generated by homologous recombination in embryonic stem cells and intended to represent the *Lama2-*null mutant ([@B63], [@B64]). It was revealed later that the mouse is not completely devoid of laminin α2 chain, but shows strongly reduced expression of the truncated molecule (lacking the LN domain) ([@B43]). The phenotype is severe and *dy*^W^/*dy*^W^ mice die typically 5--12 weeks after birth ([@B64]) (phenotype overview: [Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}), but some do not survive post-weaning^[1](#footnote1){ref-type="fn"}^.

Early timepoints of the disease pathology have been fairly well characterized in this mouse model ([@B72]; [@B90]), including embryonic stages (E10.5--E18.5) ([@B90]). In fact, myogenesis defects *in utero* have been pinpointed in *dy*^W^/*dy*^W^ mice ([@B90]). While no obvious defects of muscle development have been demonstrated in LAMA2-CMD before ([@B63]; [@B28]), myofibers are smaller at birth and muscle degeneration/regeneration occurs shortly after birth in patients ([@B51]; [@B119]). Additionally, reduction of fetal movements has been reported ([@B56]). Hence, it is reasonable to consider muscle developmental abnormalities in LAMA2-CMD (even if they are subtle).

Although myotomal (E10.5), primary (E11.5--E13.5) and the first stages of secondary myogenesis (E14.5--E16.5) proceed normally in *dy*^W^/*dy*^W^ mice, the final stages of fetal myogenesis (E17.5--E18.5) are marked with a few abnormalities (studied in epaxial muscles). The developmental defects include decreased number of Pax7 and myogenin positive cells (secondary myogenesis, E17.5 onward), smaller muscles (E18.5 onward), which results in muscle growth impairment that is not recovered during postnatal development ([@B90]; [Tables 2](#T2){ref-type="table"},[3](#T3){ref-type="table"}).

A few discrepancies concerning early postnatal development emerge from two separate studies: [@B90] reported no obvious morphology change in 2-day-old *dy*^W^/*dy*^W^ muscle, but alteration of muscle size (epaxial muscles), whereas [@B72] observed morphology defects in 1-day-old muscle with clearly reduced number of myofibers, but no change in muscle size (tibialis anterior). This suggests that the characteristics of pathological events could differ between muscles and one has to be careful to draw generalized conclusions when studying one muscle. Accordingly, it has been shown in older mice that tibialis anterior is more affected than triceps ([@B103]), soleus and extensor digitorum ([@B118]).

The natural history of the disease studied in *dy*^W^/*dy*^W^ limb muscles between 1 and 4-weeks of age reveals appearance of a broad range of dystrophic hallmarks ([Figure 2](#F2){ref-type="fig"} and [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. One-week old *dy*^W^/*dy*^W^ muscle is characterized with muscle fiber loss, extensive apoptosis, initiation of the inflammatory response together with the myogenic program as well as increased production of fibronectin, osteopontin and matrix remodeling proteins ([@B120]; [@B72]). A decreased number of myofibers does not correlate with loss of body weight, muscle weight, and reduction of muscle size ([@B72]), although slight body weight differences between wild-type mice and *dy*^W^/*dy*^W^ mutants have been reported for 1-week-old animals in another study ([@B120]). Upregulation of fibrillar collagens accompanies the pathology progression at week 2. Decrease in limb muscle weight coincides with the delay of the whole-body weight gain at week 3 ([@B72]). CK is significantly elevated in serum from 1-month-old *dy*^W^/*dy*^W^ mice ([@B64]) and fibrotic lesions are a signature of advanced pathology in *dy*^W^/*dy*^W^ muscle ([@B74]; [@B2]; [@B1]). Interestingly, apoptosis is less pronounced in 3--4 week-old mice compared to younger mutants ([@B72]). Basement membranes have patchy appearance in *dy*^W^/*dy*^W^ muscle ([@B81]). The dystrophic changes described above correlate with impaired muscle function ([@B81]; [@B18]; [@B121]).

Peripheral neuropathy is a prominent feature of the disease also in the *dy*^W^/*dy*^W^ mouse model ([@B64]), just like in all mouse models for LAMA2-CMD ([@B134]). Several studies have explored the phenotype of peripheral nervous system in *dy*^W^/*dy*^W^ mutant, showing myelination defects in sciatic nerve and ventral roots, smaller cross sectional area of sciatic nerve, as well as motor dysfunction and sensorimotor gating deficits at age of 4--6 weeks ([@B55]; [@B97]).

The respiratory function in *dy*^W^/*dy*^W^ mice has also been evaluated by whole-body plethysmography. However, the breath rate did not appear to change over time and may not be predictive of pathology in *dy*^W^/*dy*^W^ animals ([@B121]). Analysis of cardiac muscle in this mouse model is required.

Phenotype of *dy*^3K^/*dy*^3K^ Mice {#S2.SS3}
-----------------------------------

The *dy*^3K^/*dy*^3K^ mouse is the only available LAMA2-CMD mouse model void of laminin α2 subunit ([@B80]; [@B43]). The complete loss of laminin α2 chain conceivably contributes to the most severe phenotype and much earlier death of the *dy*^3K^/*dy*^3K^ mouse compared to other models (currently 3 weeks of age, they used to survive up to 5 weeks, but their phenotype has gradually worsened over the years in our colony at Lund University) (phenotype overview: [Figures 1](#F1){ref-type="fig"}, [2](#F1){ref-type="fig"}, [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, and [Supplementary Video 1](#VS1){ref-type="supplementary-material"}). The cause of death is most probably linked to malnutrition and respiratory difficulties ([@B31]).

No obvious development abnormalities have been detected in embryonic *dy*^3K^/*dy*^3K^ muscle (E18.5, calf muscles, thigh muscles) ([@B31]). Yet, more detailed studies are warranted in a wide range of muscles to confirm the current observations and comprehend myogenic events in *dy*^3K^/*dy*^3K^ embryos. One-day-old *dy*^3K^/*dy*^3K^ muscles display normal morphology (fiber size, number of fibers). Inflammation and abnormal expression of the extracellular matrix components have not been detected. Yet, occasional occurrence of apoptotic fibers marks the pathogenesis onset in 1-day-old *dy*^3K^/*dy*^3K^ muscle ([@B31]). This suggests that *dy*^3K^/*dy*^3K^ muscles are prone to damage already at the neonatal stage, when the mouse movements are limited to sporadic limb waddling. Muscle damage progresses quickly and already 4-day-old muscles show inflammatory response to injury. At day 7 the body weight is significantly reduced coinciding with pronounced loss of muscle fibers and inflammation ([Figure 2](#F2){ref-type="fig"}; [@B80]; [@B31]). The extracellular matrix components are massively upregulated, which is associated with muscle repair. Importantly, the severe phenotype observed at day 7 is partially ameliorated with age: at day 14 and 21 *dy*^3K^/*dy*^3K^ muscles show recovery of muscle fiber number, reduced inflammation ([Figure 2](#F2){ref-type="fig"}) and downregulation of fibronectin and collagen III ([@B31]). Yet, apoptotic fibers and regenerating fibers are present at these stages ([@B80]; [@B31]). Despite normalization of the number of myofibers, there is a decrease in fiber size and muscle mass ([@B8]; [@B31]). Likewise, although the abundance of interstitial extracellular matrix is diminished in older mutants, the levels of collagen III and fibronectin remain elevated compared to a healthy age-matched muscle ([Table 3](#T3){ref-type="table"}). CK levels are also increased in serum at that stage compared to wild-type mice ([@B36]; [@B54]). Basement membranes surrounding muscle fibers are discontinuous throughout the disease course ([@B80]; [@B34]). Similarly to other LAMA2-CMD mouse models, *dy*^3K^/*dy*^3K^ limb muscles display variety of phenotype presentation: vastus lateralis, medialis, gastrocnemius are more affected than rectus femoris, triceps and tibialis anterior ([@B31]). However, one has to be aware that complete quantitative analyses of dystrophic features in a wide range of muscles over time are missing for all mouse models.

Interestingly, the muscle function tests performed on *dy*^3K^/*dy*^3K^ mice at different ages do not necessarily correlate with muscle phenotype. For example, 7-day-old *dy*^3K^/*dy*^3K^ animals do not display significant difficulties when performing functional tests. On the contrary, 14-day-old mice show significant impairments of motor function ([@B31]).

Non-limb muscles have been studied in the *dy*^3K^/*dy*^3K^ mouse ([@B91]; [@B46]; [@B30], [@B31]). The principal extraocular muscle and intrinsic laryngeal muscles appear spared ([@B91], [@B46]), whereas accessory extraocular muscles show signs of myopathy ([@B30]). Esophagus shows mild muscular dystrophy (day 21); diaphragm, intercostal muscles, tongue, and temporalis demonstrate moderate dystrophic changes (studied at day 14 and 21). The most severe phenotype has been observed in masseter muscle (day 7, 14, and 21) ([@B30], [@B31]).

Heart muscle has not been shown to be affected in *dy*^3K^/*dy*^3K^ mouse, based on histology analysis ([@B34]; [@B29]). It might be that *dy*^3K^/*dy*^3K^ animals die too early to develop cardiac manifestations. Alternatively, the presence of laminins containing laminin α4 chain that are expressed in *dy*^3K^/*dy*^3K^ heart (Durbeej lab, unpublished data) might be sufficient to prevent cardiomyopathy in laminin α2-chain deficient mice. However, it is not excluded that cardiac function could be impaired and this needs to be verified by electrophysiology studies.

It is interesting that death of *dy*^3K^/*dy*^3K^ mouse coincides with the improvement of limb muscle phenotype, which points toward severe defects in other tissues, importance of masticatory muscles for proper nutrition, and perhaps importance of respiration maintenance. Respiratory function is yet to be analyzed in *dy*^3K^/*dy*^3K^ mice.

Demyelination of axons in sciatic nerve and in particular in ventral and dorsal roots, as well reduced size of axons (sciatic nerve) have been reported in *dy*^3K^/*dy*^3K^ mice ([@B85]; [@B32]). These defects result in reduced motor nerve conduction velocity of sciatic nerve ([@B85]). Despite that, hind limb paralysis is not clearly manifested, probably due to early death of *dy*^3K^/*dy*^3K^ animals. Additionally, epilepsy episodes have been observed (Durbeej lab, unpublished observations).

Other Mouse Models {#S2.SS4}
------------------

The moderately affected *dy/dy* mouse expresses reduced amounts of full-length laminin α2 subunit ([@B107]; [@B123]). Patients showing a similar expression defect exist ([@B89]; [@B119]). Therefore, *dy/dy* animals constitute an important addition to *dy*^2J^/*dy*^2J^, *dy*^3K^/*dy*^3K^, and *dy*^W^/*dy*^W^ murine models, especially because cardiomyopathy in *dy/dy* mouse has been clearly demonstrated (fibrotic lesions at week 8, hypertrophic cardiomyopathy as evidenced by echocardiography at week 18) ([@B101]; [@B36]). *Dy/dy* mice live between 12 and 24 weeks (or longer), weigh much less already at the age of 3 weeks and remain very weak throughout the disease course ([@B14]). They also display peripheral neuropathy ([@B69]). Initially this mouse model greatly facilitated experimental studies of the molecular pathology of the disease ([@B107]; [@B123]; [@B104]). Unfortunately, the unidentified mutation makes the model more difficult to study (genotyping is not possible, which negatively impacts breeding strategies). Hence, the use of *dy/dy* mice in research has diminished.

A point mutation (Arg to Cys) disrupting a conserved paired cysteine motif in *dy*^7J^/*dy*^7J^ mice results in mild pathology and normal laminin α2 levels ([@B94]). In contrast to the other LAMA2-CMD mouse models, basement membrane is thickened in *dy*^7J^/*dy*^7J^ muscle and normal in peripheral nerve. Yet, muscle degeneration and severe amyelination of nerve roots affect the *dy*^7J^/*dy*^7J^ mouse ([@B94]). This mouse model provides opportunities to investigate underlying mechanisms and treatments for mild forms of LAMA2-CMD and to study additional factors that could play major roles in modulating laminin-related interactions in basement membrane ([@B94]). In particular, *dy*^7J^/*dy*^7J^ mutant overthrows the dogma that the presence of basement membrane *per se* is necessary for prevention of the dystrophic phenotype.

Yet another mouse model, *dy*^6J^/*dy*^6J^, is available at Jackson Laboratories. The mutation remains to be identified but mice show progressive weakness and hind limb paralysis is visible at about 3 weeks of age^[2](#footnote2){ref-type="fn"}^. Lastly, two nowadays extinct mouse models have also been described; *dy*^8J^/*dy*^8J^ and *dy*^Pas^/*dy*^Pas^. The former was identified at Jackson Laboratories^[3](#footnote3){ref-type="fn"}^ and the latter spontaneously arose at the Pasteur Institute in Paris ([@B5]).

Molecular Aspects of Pathogenesis Studied in LAMA2-CMD Models {#S3}
=============================================================

It is difficult to study the pathogenesis of laminin α2 chain-deficiency *in vivo* in patients (ethical considerations, limited access to human material, large heterogeneity of patients). Mouse models for LAMA2-CMD help to overcome these obstacles and are excellent tools to explore molecular mechanisms of the disease. Over the years a tremendous amount of studies describing different aspects of the LAMA2-CMD pathology in mice has been collected. These include: (1) description of cellular and molecular events in laminin α2 chain-deficient muscle, (2) transgenic and gene therapy strategies to prevent the dystrophic phenotype ([Table 4](#T4){ref-type="table"}), (3) knockout strategies to prevent the dystrophic phenotype and/or understand the mechanisms of the disease ([Table 5](#T5){ref-type="table"}), and (4) pharmacological approaches to develop clinical treatment options ([Table 6](#T6){ref-type="table"}).

###### 

Summary of LAMA2-CMD mice overexpressing transgenes or AAV/lentivirus.

  **Approach**               **Transgene/AAV**                                                                            **Mouse model**     **Muscle condition and overall health**   **References**
  -------------------------- -------------------------------------------------------------------------------------------- ------------------- ----------------------------------------- -------------------------
  Extracellular matrix and   Laminin α2                                                                                   *dy*^W^/*dy*^W^     Improved                                  [@B64]
  receptor modulation                                                                                                     *dy*^2J^/*dy*^2J^   Improved                                  
                             Laminin α1                                                                                   *dy*^3K^/*dy*^3K^   Improved                                  [@B34], [@B32], [@B37];
                                                                                                                          *dy*^2J^/*dy*^2J^   Improved                                  [@B27]
                             Truncated laminin α1                                                                         *dy*^3K^/*dy*^3K^   Improved                                  [@B36]
                             AAV carrying dCas9, VP64 transactivators and single-guide RNAs targeting *Lama1* promoter.   *dy*^2J^/*dy*^2J^   Improved                                  [@B57]
                             AAV carrying Cas9, and single-guide RNAs correcting the splicing defect                      *dy*^2J^/*dy*^2J^   Improved                                  [@B59]
                             Mini-agrin                                                                                   *dy*^W^/*dy*^W^     Improved                                  [@B81];
                                                                                                                          *dy*^3K^/*dy*^3K^   Improved                                  [@B4]
                             Mini-agrin AAV1 and 9                                                                        *dy*^W^/*dy*^W^     Improved                                  [@B98], [@B97]
                             Mini-agrin + Bcl-2                                                                           *dy*^W^/*dy*^W^     Improved                                  [@B75]
                             Mini-agrin + αLNNd                                                                           *dy*^W^/*dy*^W^     Improved                                  [@B103]
                             Agrin                                                                                        *dy*^W^/*dy*^W^     Improved                                  [@B73]
                             Agrin-perlecan                                                                               *dy*^W^/*dy*^W^     Improved                                  [@B73]
                             αLNNd                                                                                        *dy*^2J^/*dy*^2J^   Improved                                  [@B70]
                             Integrin α7                                                                                  *dy*^W^/*dy*^W^     Improved                                  [@B18]
                             Galgt2/galgt2 AAV                                                                            *dy*^W^/*dy*^W^     Improved                                  [@B125]
  Apoptosis inhibition       Bcl-2                                                                                        *dy*^W^/*dy*^W^     Improved                                  [@B40]
  Promoting regeneration     IGF-1                                                                                        *dy*^W^/*dy*^W^     Improved                                  [@B66]
                             IGF-1 + Bax null                                                                             *dy*^W^/*dy*^W^     Improved                                  [@B126]
                             ADAM12                                                                                       *dy*^W^/*dy*^W^     No difference                             [@B42]
  Polyamine modulation       Smox or Amd1 lentivirus                                                                      *dy*^2J^/*dy*^2J^   Improved                                  [@B58]
                                                                                                                                                                                        

###### 

Summary of LAMA2-CMD mice lacking other genes.

  **Approach**                                       **Deletion**    **Mouse model**     **Muscle condition and overall health**                                           **References**
  -------------------------------------------------- --------------- ------------------- --------------------------------------------------------------------------------- ----------------
  Extracellular matrix and receptor modulation       Integrin α7     *dy*^3K^/*dy*^3K^   No difference                                                                     [@B29]
                                                     Dystrophin      *dy*^3K^/*dy*^3K^   Worsened                                                                          [@B30]
                                                     β-sarcoglycan   *dy*^3K^/*dy*^3K^   Worsened                                                                          [@B30]
                                                     Laminin α4      *dy*^3K^/*dy*^3K^   Overall phenotype worsened but skeletal muscle condition remains to be reported   [@B79]
                                                                     *dy*^2J^/*dy*^2J^                                                                                     
  Apoptosis inhibition                               Bax             *dy*^W^/*dy*^W^     Improved                                                                          [@B40]
  Modulation mitochondrial permeability transition   Cyclophilin D   *dy*^W^/*dy*^W^     Improved                                                                          [@B78]
  Inflammation and fibrosis modulation               Complement C3   *dy/dy*             Improved                                                                          [@B15]
                                                     Galectin-3      *dy*^3K^/*dy*^3K^   No difference                                                                     [@B38]
                                                     Osteopontin     *dy*^3K^/*dy*^3K^   Slightly worsened                                                                 [@B38]
                                                     miR-21          *dy*^3K^/*dy*^3K^   No difference                                                                     [@B82]
                                                                     *dy*^2J^/*dy*^2J^   No difference                                                                     
  Muscle growth                                      Myostatin       *dy*^W^/*dy*^W^     No difference                                                                     [@B67]
                                                                                                                                                                           

###### 

Summary of pharmacological approaches in LAMA2-CMD mice.

  **Approach**                           **Compound**                                                         **Mouse model**            **Muscle condition and overall health**   **References**
  -------------------------------------- -------------------------------------------------------------------- -------------------------- ----------------------------------------- -----------------
  Extracellular matrix modulation        Laminin-111 protein                                                  *dy*^W^/*dy*^W^            Improved                                  [@B105]
  Apoptosis inhibition                   Doxycycline                                                          *dy*^W^/*dy*^W^            Improved                                  [@B39]
                                         Omigapil                                                             *dy*^W^/*dy*^W^            Improved                                  [@B22]; [@B130]
                                                                                                              *dy*^2J^/*dy*^2J^          Improved                                  
                                         Omigapil in combination with mini-agrin transgene                    *dy*^W^/*dy*^W^            Improved                                  [@B75]
  Proteasome inhibition                  MG-132                                                               *dy*^3K^/*dy*^3K^          Improved                                  [@B8]
                                         Bortezomib                                                           *dy*^3K^/*dy*^3K^          Improved                                  [@B62]; [@B61]
                                                                                                              *dy*^2J^/*dy*^2J^          No difference                             
  Autophagy inhibition                   3-methyladenine                                                      *dy*^3K^/*dy*^3K^          Improved                                  [@B9]
  Inflammation and fibrosis modulation   Losartan                                                             *dy*^2J^/*dy*^2J^          Improved                                  [@B20]; [@B118]
                                                                                                              *dy*^W^/*dy*^W^            Improved                                  
                                         Losartan derivative                                                  *dy*^W^/*dy*^W^            Improved                                  [@B74]
                                         Losartan and IGF-1 transgene                                         *dy*^W^/*dy*^W^            Improved                                  [@B1]
                                         Losartan and growth hormone                                          *dy*^W^/*dy*^W^            Improved                                  [@B1]
                                         Halofuginone                                                         *dy*^2J^/*dy*^2J^          Improved                                  [@B86]
                                         Glatiramer acetate                                                   *dy*^2J^/*dy*^2J^          Improved                                  [@B16]
                                         Prednisolone                                                         *dy/dy*                    Improved                                  [@B15]
  Muscle growth                          Clenbuterol                                                          *dy/dy*                    Improved                                  [@B52]
                                         IPLEX                                                                *dy*^W^/*dy*^W^;*Bax-/-*   Improved                                  [@B126]
  Calcium modulation                     Caldecrin                                                            *dy/dy*                    Improved                                  [@B112]
  Metabolism modulation                  Metformin                                                            *dy*^2J^/*dy*^2J^          Improved (in females)\*                   [@B24]
  Oxidative stress inhibition            N-acetyl-L-cystein, vitamin E                                        dy^2J^/dy^2J^              Improved                                  [@B50]
  Exon skipping                          Phosphorodiamidate morpholino oligomer targeting exon 4 of *Lama2*   *dy*^3K^/*dy*^3K^          n.d.                                      [@B3]

\*Some minor beneficial effects were also noted in males. n.d., not determined.

Cellular and Molecular Events in Murine Laminin α2 Chain-Deficient Muscle {#S3.SS1}
-------------------------------------------------------------------------

Loss/reduction/truncation of laminin α2 subunit triggers secondary molecular changes in skeletal muscle. These changes lead to disruption of muscle homeostasis, but some of them may also constitute compensatory alterations. For example, a compensatory upregulation of laminin α4 and α5 subunits in LAMA2-CMD mouse models has been described ([@B104]; [@B81]; [@B34], [@B37]; [@B70]). Laminin α4 and laminin α5 chains do not bind equally well to α-dystroglycan compared to laminin α1 and α2 subunits ([@B110], [@B111]; [@B23]) and laminin α4 chain is also devoid of a domain that is essential for laminin polymerization ([@B133]). Therefore, this upregulation only partially prevents a more acute disease progression ([@B119]). Ablation of laminin α4 in *dy*^3K^/*dy*^3K^ and *dy*^2J^/*dy*^2J^ mice apparently worsened the phenotype (*dy*^3K^/*dy*^3K^ double mutant reported to die before 2 weeks of age) but the skeletal muscle phenotype remains to be characterized ([@B79]). Hence, the role of laminin α4 chain in LAMA2-CMD is not entirely clear. Yet, it is possible to enhance polymerization and muscle cell binding of compensatory laminin chains and this strategy has been used to boost the phenotype of laminin α2 chain-deficient mice ([@B81]; [@B73]; [@B70]; [@B103]) (mini-agrin or agrin overexpression that re-establishes connection between laminin α4 chain and dystroglycan; overexpression of laminin/nidogen chimeric protein that provides polymerization domain and combinatorial approach using both mini-agrin and the chimeric protein, see also section "Laminin α2 Chain-Deficient Mice Overexpressing Transgenes or Lacking Other Genes").

The laminin α2 chain receptor integrin α7 (forming a dimer with the β1 subunit) is lost from the sarcolemma of laminin α2 chain-deficient muscle ([@B113]; [@B53]; [@B12]; [@B34], [@B33]; [@B18]). Dystroglycans, on the other hand (both α and β), are upregulated ([@B33]). It is not excluded that other, yet unidentified, laminin receptors in muscle are also perturbed.

Impaired interactions between laminin α2 and its binding partners instigate alternations of signaling pathways. Mouse models for LAMA2-CMD have provided an excellent platform for studies of signaling events. Signaling cascades associated with apoptosis, inflammation, metabolism, regeneration, protein turnover, and fibrosis (GAPDH-Siah1-CBP/p300-p53, Akt, TGF-β, NFκB, p53, JAK/STAT, to mention a few) have been shown to be affected in laminin α2 chain-deficient murine muscle ([@B40], [@B39]; [@B22]; [@B8], [@B9]; [@B66]; [@B74]; [@B21]; [@B17]; [@B72]; [@B2]; [@B25]; [@B38], [@B31]; [@B90]; [@B93]; [@B129]). Additionally, microarray, RNA-sequencing and proteomic technologies were applied to study murine LAMA2-CMD dystrophic muscle and provided a global overview of the gene and protein expression changed upon laminin α2 chain-deficiency ([@B114]; [@B45]; [@B17]; [@B59]; [@B83]; [@B127]). Such findings are essential to capitalize on opportunities given by preclinical studies and advance toward treatment design.

Analysis of cellular events in dystrophic muscle comes hand in hand with the studies of molecular interactions. A lot of attention has been given to regeneration and cells that could repair damaged muscle (satellite cells, myoblasts, non-muscle cells with myogenic potential). The subset of proliferating pro-regenerative cells has been shown to be diminished in *dy*^W^/*dy*^W^ muscle ([@B41]), resulting in myogenesis impairment and differentiation delay in laminin α2 chain-deficient muscle ([@B65]; [@B66]; [@B72]). Consequently, cell therapy approaches have been implemented in *dy/dy, dy^W^/dy^W^*, and *dy*^3K^/*dy*^3K^ mice to support muscle renewal (myoblast, bone marrow and CD90-positive cells transplantation, manipulated mesoangioblasts) ([@B117], [@B116]; [@B48]; [@B26]; [@B19]). Further studies exploring the properties of adult stem cells in laminin α2 chain-deficient muscular dystrophy are warranted, especially in the light of the enormous impact of the basement membranes on the stem cell niche remodeling in muscle ([@B102]).

Muscle regeneration, inflammation and fibrosis are tightly connected in muscular dystrophy and this venue has, to some extent, been explored in mouse models for LAMA2-CMD. There is a thin line between correct tissue repair and uncontrolled fibrosis. It is all about "getting the balance right" and the balancing factor is inflammation ([@B95]; [@B60]; [@B106]). Since fibrosis is a signature of LAMA2-CMD ([@B84]; [@B119]; [@B20]; [@B72]; [@B2]), inflammation should take a central spot in aiming at disease prevention. Yet, not that much is known about the inflammatory response in LAMA2-CMD, but probably it is crucial for the initial wave of muscle repair ([@B38], [@B31]). Monocytes, macrophages and neutrophils, the elements of innate immune response, constitute inflammatory infiltrates at the site of muscle damage in laminin α2 chain mutants ([@B15]; [@B66]; [@B120]; [@B74]; [@B38]). Also, cytokines de-regulation has been demonstrated in laminin α2 chain-deficient murine muscle ([@B120]; [@B38]). Much less is known about adaptive immunity and role of lymphocytes in laminin α2 chain-deficiency, although a few T lymphocytes have been identified in laminin α2 chain-deficient muscle ([@B105]). Even if fibrosis has a destructive impact on condition of dystrophic muscle, myofibroblasts and fibroblasts have not been studied in LAMA2-CMD mouse models.

In summary, more effort should be dedicated to decipher interactions between cells involved in muscle regeneration, inflammation and fibrosis in LAMA2-CMD mouse models. Such studies could provide answers to mechanisms of human pathology and identify molecular targets for therapy of muscle wasting diseases.

Laminin α2 Chain-Deficient Mice Overexpressing Transgenes or Lacking Other Genes {#S3.SS2}
--------------------------------------------------------------------------------

The different LAMA2-CMD mouse models have been vital tools for the identification of disease driving mechanisms and for developing therapeutic approaches. *Dy/dy, dy^2J^/dy^2J^*, *dy*^W^/*dy*^W^, and *dy*^3K^/*dy*^3K^ mice have been genetically manipulated to overexpress or knockout specific genes that were hypothesized to impact disease pathogenesis or serve as suitable therapy candidates ([Tables 4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}). Moreover, successful gene editing by CRISPR-Cas9 has been performed to correct the splicing defect in *dy*^2J^/*dy*^2J^ animals ([@B59]; [Table 4](#T4){ref-type="table"}). Correcting the primary underlying abnormality, which is loss of laminin α2 chain, and amending the subsequent disruption of the linkage between the basement membrane and the cytoskeleton, is probably the most attractive therapeutic goal for LAMA2-CMD. Consequently, laminin α2 and α1 transgenes, respectively, have been overexpressed in *dy*^W^/*dy*^W^,*dy*^3K^/*dy*^3K^, and *dy*^2J^/*dy*^2J^ mice, conferring excellent amelioration of the dystrophic phenotype ([@B64]; [@B27]; [@B34], [@B37]; [Table 4](#T4){ref-type="table"}). More recently, overexpression of laminin α1 chain in *dy*^2J^/*dy*^2J^ mice was achieved with an adeno-associated virus carrying a catalytically inactive Cas9 with VP64 transactivators and single guide RNAs that target the *Lama1* promoter ([@B57]; [Table 4](#T4){ref-type="table"}).

The primary defect of the disease was also targeted through clever molecular strategies that aimed at restoring the linkage between the extracellular matrix and cytoskeleton without the necessity of introducing the whole laminin α2 or α1 chain. Transgenic or AVV-mediated overexpression of mini-agrin alone ([@B81]; [@B98]) or in particular mini-agrin transgene in combination with αLNNd transgene (a laminin/nidogen chimeric protein) ([@B103]) resulted in superb skeletal muscle restoration in *dy*^W^/*dy*^W^ mice ([Table 4](#T4){ref-type="table"}). Mini-agrin together with the anti-apoptotic Bcl-2 transgene also profoundly reduced muscular dystrophy in *dy*^W^/*dy*^W^ mice ([@B75]; [Table 4](#T4){ref-type="table"}). Moreover, mini-agrin overexpression has been evaluated in *dy*^3K^/*dy*^3K^ mice (very good muscle restoration) ([@B4]) but not the more attractive combination of mini-agrin and αLNNd. Additionally, αLNNd overexpression alone was shown to correct muscular dystrophy in *dy*^2J^/*dy*^2J^ animals ([@B70]; [Table 4](#T4){ref-type="table"}).

[@B125] tested another way to modulate the extracellular matrix in *dy*^W^*dy*^W^ mice. Cytotoxic T cell GalNAc transferase is an acetylgalactosaminyl-transferase that creates a CT-carbohydrate on selected glycoproteins and glycolipids. When overexpressed extrasynaptically in *dy*^W^*dy*^W^ muscle, muscular dystrophy was reduced ([Table 4](#T4){ref-type="table"}).

Genetic manipulations have also been used to evaluate the roles of the laminin α2 chain receptor integrin α7 and the members of the dystrophin-glycoprotein complex (DGC) in the LAMA2-CMD disease pathology in the different mouse models. Overexpression of integrin α7 (that is absent from the sarcolemma in LAMA2-CMD muscle) reduced muscular dystrophy in *dy*^W^/*dy*^W^ mice ([@B18]; [Table 4](#T4){ref-type="table"}). Deletion of integrin α7, on the other hand, did not aggravate the disease symptoms in *dy*^3K^/*dy*^3K^ mice, indicating that laminin α2 chain and integrin α7 have complementary functions in skeletal muscle ([@B29]; [Table 5](#T5){ref-type="table"}). In contrast, deficiency of dystrophin and β-sarcoglycan, respectively, severely worsened the phenotype of *dy*^3K^/*dy*^3K^ mice ([@B30]; [Table 5](#T5){ref-type="table"}). These results suggested non redundant roles of laminin α2 and the DGC and a key impact of laminin-DGC axis on muscle homeostasis. At the same time, studies with *dy*^3K^/*dy*^3K^ mice overexpressing laminin α1 chain with preserved integrin α7 binding domains but lacking dystroglycan binding sites emphasized the significance of both linkages in rescuing the dystrophic phenotype in muscle ([@B36]; [Table 4](#T4){ref-type="table"}).

As the dystrophic LAMA2-CMD pathology is very complex, a great deal of effort has been aimed at elucidating the secondary pathogenic mechanisms. For example, augmented apoptosis, proteasomal activity and autophagy as well as impaired mitochondrial function, excessive inflammation and pathological fibrosis are all major disease drivers in LAMA2-CMD (see also section "Cellular and Molecular Events in Murine Laminin α2 Chain-Deficient Muscle"). Accordingly, genetic approaches that target some of these secondary pathologies have been assessed in the different mouse models. Both transgenic overexpression of the anti-apoptotic protein Bcl2 and deletion of the pro-apoptotic protein Bax reduced muscular dystrophy in *dy*^W^/*dy*^W^ mice ([@B40]; [Tables 4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}) and removal of the mitochondrial calcium regulator cyclophilin D, which regulates mitochondrial permeability transition pore, attenuated muscular dystrophy in *dy*^W^/*dy*^W^ mice ([@B78]; [Table 5](#T5){ref-type="table"}).

As LAMA2-CMD skeletal muscle is characterized by early acute inflammation and subsequent fibrosis, a few studies have investigated the roles of certain pro-inflammatory and pro-fibrotic molecules in disease pathogenesis. Deletion of osteopontin and galectin-3 (both involved in inflammatory and fibrotic processes), respectively, did not reduce muscle pathology in *dy*^3K^/*dy*^3K^ mouse. In fact, removal of osteopontin slightly worsened the phenotype indicating that osteopontin might be a beneficial immunomodulator in LAMA2-CMD ([@B38]). Similarly, absence of pro-fibrotic miR-21 in *dy*^3K^/*dy*^3K^ and *dy*^2J^*dy*^2J^ mice did not improve muscular dystrophy ([@B82]). Complement 3-deficiency, on the other hand, prolonged survival in *dy/dy* mice ([@B15]; [Table 5](#T5){ref-type="table"}). Although genetic manipulations of osteopontin, galectin-3 and miR-21 in LAMA2-CMD mice did not reveal any major impact on development on fibrosis, pharmacological treatment with compounds that target inflammation and fibrosis has successfully been employed in *dy*^W^/*dy*^W^ and *dy*^2J^/*dy*^2J^ mice (these compounds and other pharmacological strategies will briefly be described below in section "Pharmacological Approaches in the Mouse Models for LAMA2-CMD").

Moreover, several attempts to boost regeneration in LAMA2-CMD mouse models have been performed. For example, transgenically overexpressed IGF-1 very well improved the outcome of *dy*^W^/*dy*^W^ mice ([@B66]; [Table 4](#T4){ref-type="table"}). In contrast, overexpression of ADAM12 or removal of myostatin, respectively, did no reduce muscular dystrophy in *dy*^W^/*dy*^W^ mice ([@B42]; [@B67]; [Tables 4](#T4){ref-type="table"},[5](#T5){ref-type="table"}).

Finally, [@B58] recently identified imbalanced polyamine metabolism in *dy*^2J^/*dy*^2J^ tibialis anterior muscle and developed a strategy to increase the polyamine level by lentiviral-mediated overexpression of adenosylmethionine decarboxylase (Amd1) and spermine oxidase (Smox) ([Table 4](#T4){ref-type="table"}).

Pharmacological Approaches in the Mouse Models for LAMA2-CMD {#S3.SS3}
------------------------------------------------------------

The genetic interventions described above are undoubtedly important for the development of therapeutic approaches for LAMA2-CMD. Yet, the translation of several of these lines of attack into clinical practice remains challenging. For this reason, a number of pharmacological approaches have been investigated in the different mouse models and could ultimately permit clinical treatment possibilities. The approaches include targeting both the primary gene deficiency as well as the secondary disease drivers. Burkin and co-workers have elegantly demonstrated that laminin-111 protein therapy reduces muscular dystrophy and improves muscle repair in **dy*^W^/*dy*^W^*mice ([@B105]; [@B115]). Apoptosis inhibition has also been evaluated with pharmacological compounds. Doxycycline and omigapil, respectively, decreased muscle pathology in **dy*^W^/*dy*^W^* mice and omigapil also had beneficial effects in **dy*^2J^/*dy*^2J^* mice ([@B40]; [@B22]; [@B130]). Similarly, proteasome inhibition with MG-132 and bortezomib, respectively, and autophagy inhibition with 3-methyladenine amended some of the pathological features in **dy*^3K^/*dy*^3K^* mice ([@B8], [@B9]; [@B62]). Additionally, compounds that modulate inflammation (glatiramer acetate, prednisolone) ([@B15]; [@B16]; [@B100]) and anti-fibrotic compounds (halofuginone, losartan, and losartan derivative) have been shown to diminish muscle pathology in **dy/dy**, **dy*^2J^/*dy*^2J^*, and**dy*^W^/*dy*^W^* mice ([@B86]; [@B20]; [@B74]; [@B118]). Lastly, compounds that modulate muscle growth (clenbuterol), calcium levels (caldecrin), metabolism (metformin), oxidative stress as well as exon skipping with phosphoroamidate morpholino oligomers have all shown a positive influence on the muscle phenotype in the different LAMA2-CMD mouse models ([@B52]; [@B112]; [@B3]; [@B24]; [@B50]; [Table 6](#T6){ref-type="table"}).

Considering that many different cellular functions are dysregulated in LAMA2-CMD, there have been a few reports describing strategies that simultaneously target diverse processes. Indeed, it was demonstrated that amelioration of pathology was greater with a combination of mini-agrin and Bcl-2 transgenes than single mode therapies. Similarly, a combination of mini-agrin and omigapil resulted in excellent muscle condition ([@B75]; [Tables 4](#T4){ref-type="table"}, [6](#T6){ref-type="table"}). Girgenrath and co-workers have also evaluated combinatorial treatment and demonstrated that a combination of IGF-1 transgene and removal of Bax profoundly ameliorated disease pathology in *dy*^W^/*dy*^W^ mice and so did removal of Bax in combination with systemic recombinant human IGF-1 (IPLEX) ([@B126]; [Tables 4--6](#T4){ref-type="table"}). Moreover, a combinatorial treatment utilizing transgenic IGF-1 in conjunction with losartan led to remarkable reduction of muscular dystrophy in *dy*^W^/*dy*^W^ mice and also growth hormone enhanced losartan treatment in *dy*^W^/*dy*^W^ mice ([@B1]; [Table 6](#T6){ref-type="table"}).

Discussion {#S4}
==========

Mouse models for LAMA2-CMD have facilitated our understanding of the disease for over two decades. During that time the research community has tried to address important disease-related questions: from the basic phenotype description, through strategies to prevent the disorder by the most obvious transgenic means (introducing the laminin α2 and α1 transgenes) or the more sophisticated molecular manipulations (combination of engineered transgenes, genome editing with CRISPR/Cas9), through pharmacological approaches to target the disease symptoms.

We are now facing a number of questions that need to be answered in order to advance the research on LAMA2-CMD. What is next? How can we use the available animal models in the best possible way? What should we focus on? Would it be justified and feasible to mimic the disease in a bigger animal? Should we increase our interest in Drosophila, nematodes, zebrafish, frogs, and newts? Indeed, Peter Currie's work in zebrafish has substantially contributed to understanding of pathogenic mechanisms of the disease ([@B44]; [@B109]; [@B49]; [@B122]).

Is there a need for creating additional mouse models for LAMA2-CMD? For example, mice with a tissue-specific deletion of the *Lama2* gene would surely become an asset in LAMA2-CMD research. Perhaps one important task would be to identify mutations in existing mouse models (*dy/dy* and *dy*^6J^/*dy*^6J^). Additionally, we should further explore the new methods and technologies that in a robust way contribute to reliable evaluation of preclinical treatment outcomes. For example, magnetic resonance imaging, electrical impendence myography and identification of biomarkers could complement the classical histopathology evaluations and functional tests ([@B2]; [@B118]; [@B83]; [@B88]).

The reproducibility of data and well-grounded comparison of outcomes are a key to good science. One of the crucial tasks that we need to dedicate more energy to is a seemingly trivial, low-status assignment to create the standard operating procedures (SOPs) for all mouse models that all researches agree upon. Another task is to... stick to them: it is still a common practice that researchers follow their own protocols despite SOPs availability. SOPs have been generated for some of the mouse models for various muscular dystrophies/muscle diseases^[4](#footnote4){ref-type="fn"}^. Some of these protocols can be easily adapted to LAMA2-CMD mouse models ([@B31]). It is also encouraging that several SOPs have been described for *dy*^W^/*dy*^W^ mouse model^[5](#footnote5){ref-type="fn"}^. Hence, we head toward the right direction, but the researchers in the LAMA2-CMD field need to step up and focus further on this issue. For example, SOPs for *dy*^3K^/*dy*^3K^ and *dy*^2J^/*dy*^2J^ mouse models should be created.

Variability in growth rates and overall survival of *dy*^W^/*dy*^W^ animals from different laboratories have been noted ([@B121]) and such discrepancies are likely to occur for the other mouse models as well. Therefore, it may be highly relevant to replicate the different therapeutic strategies in different mouse models and in different laboratories (even though such studies will be difficult to publish). It is also essential to thoroughly analyze the onset of pathological features in the variety of muscles in LAMA2-CMD mouse models in order to choose optimal time-points for preclinical interventions (despite the fact that most patients today may not be treated before the disease onset in the corresponding clinical set up) and select the most relevant muscles for treatment evaluation.

Thus far we face an incomplete picture of pathology in different muscle types. Considering that only in the hind limb and pelvis of a mouse there are 39 muscles ([@B10]), very few muscles have been analyzed in LAMA2-mouse models. What is more, only selected dystrophic features (for example, only fibrosis) and a limited range of time-points have been described in most publications (see references in [Tables 4--6](#T4){ref-type="table"}). Therefore, assessments of muscle phenotypes lack a quantitative aspect and are often based on general morphology and a researcher's perception. Again, potential studies that aim at filling those gaps do not align with current publishing and funding policies. As a result, they are rarely prioritized. Coordinated effort between different laboratories should be undertaken to focus on quantitative methods, time points and muscles of choice. In general, natural history studies, standardization of outcome measures, reporting of negative findings and importance of data validation should be further emphasized. Notably, the researchers are not on their own in these efforts. Patients' organizations (for example, Cure CMD^[6](#footnote6){ref-type="fn"}^) understand the significance of such studies and greatly support basic research.

Exploring treatment strategies in a preclinical setup is a challenging and attractive goal for scientists that work with animal models. However, it has become clear that deeper understanding of pathogenic mechanisms underlying the disease development needs to be focused on. In particular, signaling pathways and involvement of different cell types in LAMA2-CMD pathology could be crucial for therapy design. Apart from well-known abnormalities in the central and peripheral nervous system (that are manifested both in LAMA2-CMD patients and mouse models) ([@B11]; [@B99]; [@B6]; [@B7]; [@B76]), more subtle extramuscular defects are evident in mice (e.g., hearing loss, impaired spermatogenesis, and aberrant development of thymocytes and odontoblasts) ([@B68]; [@B96]; [@B131]; [@B47]). These aspects of LAMA2-CMD together with the central nervous system manifestations have been poorly studied. Similarly, other tissues that normally express laminin α2 chain (heart, smooth muscle) have not been fully evaluated.

Altogether, animal models are an attractive platform to investigate the variety of the disease symptoms and treatment strategies. Nevertheless, it is important to bear in mind that relatively few preclinical findings will be successfully translated to humans as mice do not always truthfully model human disease pathology. This diminishes the predictive value of animal-based discoveries for future clinical studies ([@B35]). But if only one sole finding is positively verified and could be implemented in humans, it would be a huge achievement. It all boils down to cumulated effort to properly validate preclinical results and carefully choose targets for clinical trials. That is especially important for LAMA2-CMD where a limited pool of patients for clinical test is available. The take-home message is that we have to keep going: even if the alternatives for animal research become more and more useful (induced pluripotent stem cells, human cell-based assays), they suffer from various limitations: they cannot mimic multiple interactions between various tissues, organs and immune system. In addition, pharmacokinetic/pharmacodynamic modeling is not feasible using these methods. Consequently, they are not robust enough to provide reliable verification platform for such a complex disease. Hence, the mouse models still offer the best chance for important discoveries and preclinical studies for muscular dystrophies like LAMA2-CMD will certainly remain fully dependent on animals.

Conclusion {#S5}
==========

In summary, we believe that research opportunities on the mouse models for LAMA2-CMD will continue to inspire us, scientists, and spur our joint effort to design effective treatment for the disease.
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A 3-week-old *dy*^3K^/*dy*^3K^ mouse and a wild-type littermate. The *dy*^3K^/*dy*^3K^ mouse is not active when placed in a new cage.
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Click here for additional data file.
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